SKF-89,626

From WikiMD's WELLNESSPEDIA

SKF-89,626

SKF-89,626 is a synthetic compound that acts as a selective agonist for the dopamine D1 receptor. It is primarily used in scientific research to study the role of D1 receptors in the brain and their involvement in various neurological and psychiatric conditions.

Chemical Structure and Properties[edit]

SKF-89,626 is chemically classified as a benzazepine derivative. Its IUPAC name is 6-chloro-7,8-dihydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine. The compound has a molecular formula of C17H18ClNO2 and a molecular weight of 303.79 g/mol.

Pharmacology[edit]

SKF-89,626 is known for its high affinity and selectivity for the dopamine D1 receptor, a subtype of dopamine receptor that is primarily expressed in the central nervous system. Activation of D1 receptors by SKF-89,626 leads to increased production of cyclic AMP (cAMP) within neurons, which is a key second messenger involved in many cellular processes.

Mechanism of Action[edit]

As a D1 receptor agonist, SKF-89,626 mimics the action of dopamine by binding to the D1 receptor and activating it. This activation results in the stimulation of adenylate cyclase, an enzyme that converts ATP to cAMP. The increase in cAMP levels subsequently activates protein kinase A (PKA), which phosphorylates various target proteins, leading to changes in neuronal activity and gene expression.

Research Applications[edit]

SKF-89,626 is widely used in research to explore the role of D1 receptors in:

  • Cognition and Memory: Studies have shown that D1 receptor activation can enhance cognitive functions such as working memory and attention.
  • Motor Control: D1 receptors are involved in the regulation of motor activity, and SKF-89,626 is used to study disorders like Parkinson's disease.
  • Psychiatric Disorders: Research on SKF-89,626 helps in understanding the pathophysiology of schizophrenia and other mood disorders where dopamine dysregulation is implicated.

Safety and Toxicology[edit]

While SKF-89,626 is a valuable research tool, it is not approved for clinical use in humans. Studies in animal models have shown that excessive activation of D1 receptors can lead to adverse effects such as hyperactivity and stereotypic behaviors.

Also see[edit]

References[edit]


External Links[edit]

Template:Dopaminergic drugs

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=SKF-89,626&oldid=6618643"